Literature DB >> 15378550

Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2.

Thomas W Prior1, Kathryn J Swoboda, H Denman Scott, Ashley Q Hejmanowski.   

Abstract

Spinal muscular atrophy is a common autosomal recessive neuromuscular disorder caused by the homozygous loss of the SMN1 gene. The absence of the SMN1 gene has been shown to occur in all types of SMA, childhood and adult forms. In rare cases, asymptomatic family members have also been found with homozygous mutations in the SMN1 gene, suggesting a role for phenotypic modifiers. We describe three unrelated asymptomatic individuals, with family histories of SMA, who were shown to have the homozygous SMN1 deletion. Quantitative studies indicated that the three individuals all had increased SMN2 copy numbers. These cases not only support the role of SMN2 in modifying the phenotype, but our data also demonstrate that expression levels consistent with five copies of the SMN2 genes maybe enough to compensate for the absence of the SMN1 gene. Lastly, in cases similar to the ones described, the measurement of the SMN2 gene copy number may provide valuable prognostic information.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378550      PMCID: PMC4349519          DOI: 10.1002/ajmg.a.30251

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  18 in total

Review 1.  When is a deletion not a deletion? When it is converted.

Authors:  A H Burghes
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

2.  A mouse model for spinal muscular atrophy.

Authors:  H M Hsieh-Li; J G Chang; Y J Jong; M H Wu; N M Wang; C H Tsai; H Li
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

3.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

Authors:  P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

Authors:  Markus Feldkötter; Verena Schwarzer; Radu Wirth; Thomas F Wienker; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

5.  Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype.

Authors:  L Campbell; A Potter; J Ignatius; V Dubowitz; K Davies
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

Review 6.  Animal models of spinal muscular atrophy.

Authors:  U R Monani; D D Coovert; A H Burghes
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

7.  Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy.

Authors:  J Pearn
Journal:  J Med Genet       Date:  1978-12       Impact factor: 6.318

8.  Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1.

Authors:  Claudia Helmken; Yvonne Hofmann; Frank Schoenen; Gabriela Oprea; Heidrun Raschke; Sabine Rudnik-Schöneborn; Klaus Zerres; Brunhilde Wirth
Journal:  Hum Genet       Date:  2003-10-01       Impact factor: 4.132

9.  Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2.

Authors:  Matthew D Mailman; John W Heinz; Audrey C Papp; Pamela J Snyder; Mary S Sedra; Brunhilde Wirth; Arthur H M Burghes; Thomas W Prior
Journal:  Genet Med       Date:  2002 Jan-Feb       Impact factor: 8.822

10.  Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy.

Authors:  C Brahe; S Servidei; S Zappata; E Ricci; P Tonali; G Neri
Journal:  Lancet       Date:  1995-09-16       Impact factor: 79.321

View more
  60 in total

1.  PLS3 expression and SMA phenotype: a commentary on correlation of PLS3 expression with disease severity in children with spinal muscular atrophy.

Authors:  Hisahide Nishio
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

2.  Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy.

Authors:  Cao Yanyan; Qu Yujin; Bai Jinli; Jin Yuwei; Wang Hong; Song Fang
Journal:  J Hum Genet       Date:  2013-10-31       Impact factor: 3.172

Review 3.  Disease mechanisms and therapeutic approaches in spinal muscular atrophy.

Authors:  Sarah Tisdale; Livio Pellizzoni
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

Review 4.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

5.  A common spinal muscular atrophy deletion mutation is present on a single founder haplotype in the US Hutterites.

Authors:  Jessica X Chong; A Afşin Oktay; Zunyan Dai; Kathryn J Swoboda; Thomas W Prior; Carole Ober
Journal:  Eur J Hum Genet       Date:  2011-05-25       Impact factor: 4.246

6.  Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspectives.

Authors:  Candice Meldrum; Charles Scott; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

7.  SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

8.  Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors.

Authors:  Amanda Carré; Candice Empey
Journal:  J Genet Couns       Date:  2015-08-08       Impact factor: 2.537

9.  A positive modifier of spinal muscular atrophy in the SMN2 gene.

Authors:  Thomas W Prior; Adrian R Krainer; Yimin Hua; Kathryn J Swoboda; Pamela C Snyder; Scott J Bridgeman; Arthur H M Burghes; John T Kissel
Journal:  Am J Hum Genet       Date:  2009-08-27       Impact factor: 11.025

10.  SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy.

Authors:  John T Kissel; Bakri Elsheikh; Wendy M King; Miriam Freimer; Charles B Scott; Stephen J Kolb; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2014-02       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.